Bought VVUS at 11.40 as they claim weight-loss drug QNEXA is a cure for lard-ass (a very common medical condition). Sold LPIH and CMTP on recent pops.
10:29 Vivus jumps ~0.40 as takeover rumor makes the rounds (11.57 +0.32)
Excerpt from 9/9/2009 news:
CEO Wilson is optimistic that Qnexa's strong data will capture the industry's attention. He said he plans to sit down with interested parties, along with Chief Operating Officer Peter Tam, rather than hire outside advisers to negotiate for the company.
"It won't be a banker, I'll tell you that right now," he said. "We know the drug, we know its potential and we know what it is worth."
Although Vivus is looking for a sales partner, larger companies may be more interested in buying the company outright, a situation that is familiar to Wilson.
When he worked for Syntex Corp., it was acquired by Roche Holding AG (RHHBY), and when he worked for LifeScan Inc., it was bought by Johnson & Johnson (JNJ).
"I have no choice in this matter," he said. "When they come knocking on the door, you can either play with them [on the price of a deal] or they can take it out to a shareholder vote."
'peeker
Back fm 2wks in Montana, Wyoming, and Idaho.
Double rainbow & cat-tails at Nine Pipes National Bird Sanctuary.
![](//investorshub.advfn.com/uimage/uploads/2009/9/14/hexbtCat_Tails_and_Rainbow.JPG)